Details of Disease

General Information of Disease (ID: DIS8KNVF)

• Disease Name: Chagas disease
• Synonyms: south American trypanosomiasis; infection caused by trypanosoma cruzi; Chagas-mazza disease; American trypanosomiasis; infection by trypanosoma cruzi; Trypanosoma cruzi infectious disease; Trypanosoma cruzi disease or disorder; Trypanosoma cruzi caused disease or disorder; Chagas' disease with other organ involvement; Chagas' disease with nervous system involvement; Chagas' disease with digestive system involvement; Chagas' disease; Chagas disease
• Disease Class: 1F53: Chagas disease
• Definition: A parasitic infection caused by Trypanosoma cruzi. It is transmitted by insect bites. It is characterized by an acute and chronic phase; in the acute phase patients may have fever, malaise, and swelling at the site of the insect bite. In the chronic phase patients develop hepatosplenomegaly, lymphadenopathy, cardiomyopathy and arrhythmias.
• Disease Hierarchy:
  DISUBO83: Trypanosomiasis
  DISEM33Q: Infectious disease
  DISGFCIX: Vector-borne disease
  DIS8KNVF: Chagas disease
• ICD Code:
  ICD-11: ICD-11: IF53
  Expand ICD-11: '1F53
  Expand ICD-10: 'B57; 'B57.4; 'B57.5
• Disease Identifiers:
  MONDO ID: MONDO_0001444
  MESH ID: D014355
  UMLS CUI: C0041234
  MedGen ID: 11935
  Orphanet ID: 3386
  SNOMED CT ID: 77506005

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Benznidazole	DMC83EU	Approved	Small molecular drug	[1]
Nifurtimox	DMSQLZJ	Approved	Small molecular drug	[2]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 14 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CCR5	TTJIH8Q	Limited	Biomarker	[3]
CYP51A1	TT67TDP	Limited	Biomarker	[4]
BACE1	TTJUNZF	Strong	Biomarker	[5]
DHODH	TTLVP78	Strong	Biomarker	[6]
DYSF	TTA7MXQ	Strong	Altered Expression	[7]
HEXIM1	TTFOKAH	Strong	Biomarker	[8]
KIR2DL2	TTU0P73	Strong	Biomarker	[9]
KIR2DS2	TTV3CFI	Strong	Biomarker	[9]
KNG1	TTDJ4MY	Strong	Biomarker	[10]
MASP2	TTR01E9	Strong	Biomarker	[11]
PDE2A	TTJGW1Z	Strong	Biomarker	[12]
PLCB1	TTLPGU7	Strong	Biomarker	[12]
TMPRSS11D	TTWHYC8	Strong	Biomarker	[13]
VIPR2	TT4O5P0	Strong	Genetic Variation	[14]

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ATP2B1	DTJWQ1L	Strong	Biomarker	[12]
SLC25A31	DTYDHJI	Strong	Biomarker	[15]

This Disease Is Related to 35 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADAM7	OTHF38RR	Strong	Biomarker	[16]
AMZ1	OTDH9XM0	Strong	Biomarker	[17]
ARHGEF10	OTHJ1Y4I	Strong	Biomarker	[12]
ATP2A3	OTFYDEES	Strong	Biomarker	[12]
COLEC11	OT4GC46Y	Strong	Genetic Variation	[11]
CYTB	OTAHB98A	Strong	Genetic Variation	[18]
EIF2S1	OTM0GDTP	Strong	Posttranslational Modification	[19]
EIF2S2	OTXF0B09	Strong	Posttranslational Modification	[19]
EIF2S3	OTARRES9	Strong	Posttranslational Modification	[19]
EPGN	OT3EG75W	Strong	Biomarker	[20]
GGNBP2	OT7K9YZV	Strong	Biomarker	[21]
KNTC1	OTI2OOFN	Strong	Biomarker	[22]
LY6E	OTMG16BZ	Strong	Biomarker	[23]
MAP6	OTPUI00F	Strong	Biomarker	[24]
MCU	OTQZAYWQ	Strong	Biomarker	[25]
MEF2D	OT7CEIG0	Strong	Biomarker	[12]
NDUFA5	OTR848KZ	Strong	Biomarker	[26]
NPNT	OTFZAO1G	Strong	Biomarker	[27]
NRF1	OTOXWNV8	Strong	Biomarker	[28]
OTUB1	OT8WWM9O	Strong	Biomarker	[29]
PANX1	OTXPEDOK	Strong	Biomarker	[30]
PLCB4	OTPA0QHW	Strong	Biomarker	[12]
PPP1R12A	OT4AVU95	Strong	Biomarker	[12]
RABEP2	OTO61X27	Strong	Biomarker	[31]
RO60	OTLGM5A8	Strong	Biomarker	[32]
RPIA	OT805SMH	Strong	Biomarker	[33]
RRAD	OTW2O4GD	Strong	Biomarker	[34]
SBNO1	OTNX3RL0	Strong	Biomarker	[35]
SBNO2	OT1C6J3K	Strong	Biomarker	[35]
SDC4	OTKUVUGZ	Strong	Biomarker	[36]
SKIL	OTNBXH32	Strong	Biomarker	[35]
SRM	OT4N5MDP	Strong	Biomarker	[37]
TCN2	OT41D0L3	Strong	Biomarker	[38]
TPI1	OT14KP4B	Strong	Biomarker	[39]
TRIM33	OT0KS4J7	Strong	Biomarker	[40]

References

• [1] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [3] The role of CCR5 in Chagas disease - a systematic review.Infect Genet Evol. 2016 Nov;45:132-137. doi: 10.1016/j.meegid.2016.08.012. Epub 2016 Aug 15.
• [4] Successful Aspects of the Coadministration of Sterol 14-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi.ACS Infect Dis. 2019 Mar 8;5(3):365-371. doi: 10.1021/acsinfecdis.8b00253. Epub 2019 Jan 23.
• [5] Therapeutic effects of vaccine derived from amastigote surface protein-2 (ASP-2) against Chagas disease in mouse liver.Cytokine. 2019 Jan;113:285-290. doi: 10.1016/j.cyto.2018.07.017. Epub 2018 Jul 20.
• [6] Design and synthesis of potent substrate-based inhibitors of the Trypanosoma cruzi dihydroorotate dehydrogenase.Bioorg Med Chem. 2017 Feb 15;25(4):1465-1470. doi: 10.1016/j.bmc.2017.01.009. Epub 2017 Jan 9.
• [7] Trypanosoma cruzi modulates gene expression of plasma membrane repair-related proteins.Acta Trop. 2017 Oct;174:153-157. doi: 10.1016/j.actatropica.2016.06.008. Epub 2016 Jun 8.
• [8] Rapidly progressive course of Trypanosoma cruzi infection in mice heterozygous for hexamethylene bis-acetamide inducible 1 (Hexim1) gene.Microbes Infect. 2018 Jan;20(1):25-36. doi: 10.1016/j.micinf.2017.09.001. Epub 2017 Sep 22.
• [9] Killer Cell Immunoglobulin-like Receptors and Their HLA Ligands are Related with the Immunopathology of Chagas Disease.PLoS Negl Trop Dis. 2015 May 15;9(5):e0003753. doi: 10.1371/journal.pntd.0003753. eCollection 2015 May.
• [10] Subverting bradykinin-evoked inflammation by co-opting the contact system: lessons from survival strategies of Trypanosoma cruzi.Curr Opin Hematol. 2018 Sep;25(5):347-357. doi: 10.1097/MOH.0000000000000444.
• [11] Human collectin-11 (COLEC11) and its synergic genetic interaction with MASP2 are associated with the pathophysiology of Chagas Disease.PLoS Negl Trop Dis. 2019 Apr 17;13(4):e0007324. doi: 10.1371/journal.pntd.0007324. eCollection 2019 Apr.
• [12] Genes of the cGMP-PKG-Ca(2+) signaling pathway are alternatively spliced in cardiomyopathy: Role of RBFOX2.Biochim Biophys Acta Mol Basis Dis. 2020 Mar 1;1866(3):165620. doi: 10.1016/j.bbadis.2019.165620. Epub 2019 Nov 25.
• [13] Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole.Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02515-18. doi: 10.1128/AAC.02515-18. Print 2019 Apr.
• [14] Low levels of vasoactive intestinal peptide are associated with Chagas disease cardiomyopathy.Hum Immunol. 2013 Oct;74(10):1375-81. doi: 10.1016/j.humimm.2013.06.028. Epub 2013 Jun 22.
• [15] Targeting polyamine transport in Trypanosoma cruzi.Eur J Med Chem. 2018 Mar 10;147:1-6. doi: 10.1016/j.ejmech.2018.01.083. Epub 2018 Jan 31.
• [16] Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection.PLoS Negl Trop Dis. 2014 Aug 21;8(8):e3089. doi: 10.1371/journal.pntd.0003089. eCollection 2014 Aug.
• [17] Archaea Symbiont of T. cruzi Infection May Explain Heart Failure in Chagas Disease.Front Cell Infect Microbiol. 2018 Nov 21;8:412. doi: 10.3389/fcimb.2018.00412. eCollection 2018.
• [18] High-resolution melting (HRM) of the cytochrome B gene: a powerful approach to identify blood-meal sources in Chagas disease Vectors.PLoS Negl Trop Dis. 2012;6(2):e1530. doi: 10.1371/journal.pntd.0001530. Epub 2012 Feb 28.
• [19] Identification of di-substituted ureas that prevent growth of trypanosomes through inhibition of translation initiation.Sci Rep. 2018 Mar 20;8(1):4857. doi: 10.1038/s41598-018-23259-9.
• [20] Genomic African and Native American Ancestry and Chagas Disease: The Bambui (Brazil) Epigen Cohort Study of Aging.PLoS Negl Trop Dis. 2016 May 16;10(5):e0004724. doi: 10.1371/journal.pntd.0004724. eCollection 2016 May.
• [21] Biological Activities of Novel Derivatives of Differentiation-Inducing Factor 3 from Dictyostelium discoideum.Biol Pharm Bull. 2017;40(11):1941-1947. doi: 10.1248/bpb.b17-00484.
• [22] The genetic immunization with paraflagellar rod protein-2 fused to the HSP70 confers protection against late Trypanosoma cruzi infection.Vaccine. 2006 Nov 30;24(49-50):7046-55. doi: 10.1016/j.vaccine.2006.07.006. Epub 2006 Jul 21.
• [23] Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice.Hum Vaccin Immunother. 2019;15(1):210-219. doi: 10.1080/21645515.2018.1520581. Epub 2018 Sep 21.
• [24] Development of a PCR Assay to Detect Low Level Trypanosoma cruzi in Blood Specimens Collected with PAXgene Blood DNA Tubes for Clinical Trials Treating Chagas Disease.PLoS Negl Trop Dis. 2016 Dec 1;10(12):e0005146. doi: 10.1371/journal.pntd.0005146. eCollection 2016 Dec.
• [25] The mitochondrial calcium uniporter complex in trypanosomes.Cell Biol Int. 2018 Jun;42(6):656-663. doi: 10.1002/cbin.10928. Epub 2018 Jan 25.
• [26] T cell epitope characterization in tandemly repetitive Trypanosoma cruzi B13 protein.Microbes Infect. 2005 Aug-Sep;7(11-12):1184-95. doi: 10.1016/j.micinf.2005.03.033.
• [27] The 2018 ISDE achalasia guidelines.Dis Esophagus. 2018 Sep 1;31(9). doi: 10.1093/dote/doy071.
• [28] Defects of mtDNA replication impaired mitochondrial biogenesis during Trypanosoma cruzi infection in human cardiomyocytes and chagasic patients: the role of Nrf1/2 and antioxidant response.J Am Heart Assoc. 2012 Dec;1(6):e003855. doi: 10.1161/JAHA.112.003855. Epub 2012 Dec 19.
• [29] GRAIL and Otubain-1 are Related to T Cell Hyporesponsiveness during Trypanosoma cruzi Infection.PLoS Negl Trop Dis. 2017 Jan 23;11(1):e0005307. doi: 10.1371/journal.pntd.0005307. eCollection 2017 Jan.
• [30] Trypanosoma cruzi Infection Induces Pannexin-1 Channel Opening in Cardiac Myocytes.Am J Trop Med Hyg. 2018 Jan;98(1):105-112. doi: 10.4269/ajtmh.17-0293.
• [31] Chagas disease-specific antigens: characterization of epitopes in CRA/FRA by synthetic peptide mapping and evaluation by ELISA-peptide assay.BMC Infect Dis. 2013 Dec 3;13:568. doi: 10.1186/1471-2334-13-568.
• [32] Seroprevalence and geographical distribution of sero-positive blood donors to Trypanosoma cruzi at the central blood bank of the National Medical Center "La Raza".Transfusion. 2019 Feb;59(2):639-647. doi: 10.1111/trf.15074. Epub 2018 Dec 5.
• [33] In silico identification of inhibitors of ribose 5-phosphate isomerase from Trypanosoma cruzi using ligand and structure based approaches.J Mol Graph Model. 2017 Oct;77:168-180. doi: 10.1016/j.jmgm.2017.08.007. Epub 2017 Aug 12.
• [34] 2b-RAD genotyping for population genomic studies of Chagas disease vectors: Rhodnius ecuadoriensis in Ecuador.PLoS Negl Trop Dis. 2017 Jul 19;11(7):e0005710. doi: 10.1371/journal.pntd.0005710. eCollection 2017 Jul.
• [35] Potential Utility of Protein Targets of Cysteine-S-Nitrosylation in Identifying Clinical Disease Status in Human Chagas Disease.Front Microbiol. 2019 Jan 15;9:3320. doi: 10.3389/fmicb.2018.03320. eCollection 2018.
• [36] Lack of association between serum syndecan-4, myocardial fibrosis and ventricular dysfunction in subjects with chronic Chagas disease.PLoS One. 2017 Dec 12;12(12):e0189408. doi: 10.1371/journal.pone.0189408. eCollection 2017.
• [37] In silico, in vitro, X-ray crystallography, and integrated strategies for discovering spermidine synthase inhibitors for Chagas disease.Sci Rep. 2017 Jul 27;7(1):6666. doi: 10.1038/s41598-017-06411-9.
• [38] Trypanosoma cruzi discrete typing units in Chagas disease patients from endemic and non-endemic regions of Argentina.Parasitology. 2012 Apr;139(4):516-21. doi: 10.1017/S0031182011002186. Epub 2012 Feb 6.
• [39] A monoclonal antibody that inhibits Trypanosoma cruzi growth in vitro and its reaction with intracellular triosephosphate isomerase.Parasitol Res. 2008 Mar;102(4):635-43. doi: 10.1007/s00436-007-0803-5. Epub 2007 Nov 29.
• [40] Purinergic ecto-enzymes participate in the thromboregulation in acute in mice infection by Trypanosoma cruzi.Mol Cell Biochem. 2017 Aug;432(1-2):1-6. doi: 10.1007/s11010-017-2992-2. Epub 2017 Mar 11.